Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7714492 | 0.77 | HSD11B1 (0.41) | HSD11B1CYP2C9 | |
| SCHEMBL17350313 | 0.73 | HSD11B1 (0.42) | HSD11B1CYP2C9CXCR3 | |
| SCHEMBL5256611 | 0.73 | HSD11B1 (0.38) | HSD11B1CYP2C9 | |
| SCHEMBL7712775 | 0.71 | HSD11B1 (0.37) | HSD11B1CYP2C9 | |
| SCHEMBL5253729 | 0.69 | HSD11B1 (0.35) | HSD11B1 | |
| SCHEMBL150989 | 0.69 | HSD11B1 (0.39) | HSD11B1CYP2C9 | |
| SCHEMBL630318 | 0.69 | SMN1; SMN2 (0.42) | HSD11B1 | |
| SCHEMBL20180015 | 0.69 | HSD11B1 (0.44) | HSD11B1CYP2C9CXCR3 | |
| SCHEMBL21650459 | 0.69 | HSD11B1 (0.44) | HSD11B1CYP2C9CXCR3 | |
| SCHEMBL16567928 | 0.69 | HSD11B1 (0.50) | HSD11B1CYP2C9CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0607334-B1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS | DU PONT MERCK PHARMA (US) | 1997-07-30 | — | — | EP | claimed |
| US-5650406-A | ANTISCHIZOPHRENIC AGENT | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1997-07-22 | — | — | US | claimed |
| EP-0757040-A1 | ADAMANTANE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1997-02-05 | — | — | EP | claimed |
| EP-0607334-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS. | DU PONT MERCK PHARMA (US) | 1994-07-27 | — | — | EP | claimed |
| WO-1993007128-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-04-15 | — | — | WO | claimed |
| US-11718585-B2 | Bis-cyclic guanidines as antibacterial agents | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-08-08 | — | — | US | disclosed |
| US-20220119352-A1 | BIS-CYCLIC GUANIDINES AS ANTIBACTERIAL AGENTS | NATIONAL SCIENCE FOUNDATION | 2022-04-21 | — | — | US | disclosed |
| CN-114174263-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| US-11214550-B2 | Bis-cyclic guanidines as antibacterial agents | UNIVERSITY OF SOUTH FLORIDA (US) | 2022-01-04 | — | — | US | disclosed |
| US-20200231572-A1 | NOVEL BIS-CYCLIC GUANIDINES AS ANTIBACTERIAL AGENTS | NATIONAL SCIENCE FOUNDATION | 2020-07-23 | — | — | US | disclosed |
| EP-3657947-A1 | NOVEL BIS-CYCLIC GUANIDINES AS ANTIBACTERIAL AGENTS | University Of South Florida (US) | 2020-06-03 | — | — | EP | disclosed |
| WO-2019022873-A1 | NOVEL BIS-CYCLIC GUANIDINES AS ANTIBACTERIAL AGENTS | UNIVERSITY OF SOUTH FLORIDA (US) | 2019-01-31 | — | — | WO | disclosed |
| WO-1995003285-A1 | 1,5-BENZODIAZEPINE DERIVATIVES USEFUL AS CCK OR GASTRIN ANTAGONISTS | GLAXO SPA (IT) | 1995-02-02 | — | — | WO | disclosed |
| WO-1994025445-A1 | 1,5-BENZODIAZEPINES USEFUL AS GASTRIN OR CCK-ANTAGONISTS | GLAXO S.P.A. (IT) | 1994-11-10 | — | — | WO | disclosed |
| EP-0623118-A1 | CARBAMATE DERIVATIVES AND THEIR USE IN MEDICINE | GLAXO S.p.A. (IT) | 1994-11-09 | — | — | EP | disclosed |
| EP-0607334-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS. | DU PONT MERCK PHARMA (US) | 1994-07-27 | — | — | EP | disclosed |
| EP-0558104-A1 | 1,5-Benzodiazepine derivatives and their use in medicine | GLAXO S.p.A. (IT) | 1993-09-01 | — | — | EP | disclosed |
| WO-1993014074-A1 | 1,5-BENZODIAZEPINE DERIVATIVES AND THEIR USE IN MEDICINE | GLAXO SPA (IT) | 1993-07-22 | — | — | WO | disclosed |
| WO-1993014075-A1 | CARBAMATE DERIVATIVES AND THEIR USE IN MEDICINE | GLAXO SPA (IT) | 1993-07-22 | — | — | WO | disclosed |
| WO-1993007128-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119352-A1 | BIS-CYCLIC GUANIDINES AS ANTIBACTERIAL AGENTS | GMPS, CGAS, GDA | HSD11B1 4837/4885CYP2C9 3707/4885CXCR3 1269/4885 |
| US-11718585-B2 | Bis-cyclic guanidines as antibacterial agents | GMPS, CGAS, GDA | HSD11B1 4837/4885CYP2C9 3707/4885CXCR3 1269/4885 |
| US-11214550-B2 | Bis-cyclic guanidines as antibacterial agents | GMPS, CGAS, GDA | HSD11B1 4837/4885CYP2C9 3707/4885CXCR3 1269/4885 |
| US-20200231572-A1 | NOVEL BIS-CYCLIC GUANIDINES AS ANTIBACTERIAL AGENTS | GMPS, CGAS, GDA | HSD11B1 4847/4885CYP2C9 4188/4885CXCR3 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.